Yuncheng Zhang

Yuncheng Zhang

Auto-generated profile, based on publicly available information

Yuncheng Zhang

Department of Hepatobiliary Surgery and Center of Organ Transplantation, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2016 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YZYuncheng Zhang
Yuncheng Zhang
YZYuanwen Zheng
Yuanwen Zheng
AFAli Faheem
Ali Faheem
TSTiantong Sun
Tiantong Sun
CLChunyou Li
Chunyou Li
JLJun Liu
Jun Liu
Due to frequent phosphoinositide 3‑kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway dysregulation, AKT is typically accepted as a promising anticancer therapeutic target. mTOR, in particular, represents a suitable therapeutic target for hepatocellular carcinoma, whilst suppressor with morphogenetic effect on genitalia family member‑1 (SMG‑1) is believed to serve a potential tumor suppressor role in human cancer. Despite SMG‑1 and mTOR belonging to the same PI3K‑related kinase family, the interactions between them are not yet fully understood. In the present study, a novel pyrrolopyrimidine‑derived compound, AZD5363, was observed to suppress proliferation in liver cancer Hep‑G2 and Huh‑7 cells by inhibiting the phosphorylation of downstream molecules in the AKT signal pathway, in a dose‑ and time‑dependent manner. AZD5363 activated the phosphorylation of mTOR, dependent on the liver cancer cell type, as it may have differing effects in various liver cancer cell lines. Additionally, AZD5363 also activated SMG‑1 within the same liver cancer cells types, which subsequently activated the phosphorylation of mTOR. In conclusion, the present study indicates that AZD5363 inhibited phosphorylation of AKT downstream molecules, and activated phosphorylation of mTOR and SMG‑1, dependent on the liver cancer type.

1 July 2018 in Journal of the Franklin Institute
Verified
Journal Article
Closed access
JZJianzhong Zhou
Jianzhong Zhou
YZYuncheng Zhang
Yuncheng Zhang
YZYang Zheng
Yang Zheng
YXYanhe Xu
Yanhe Xu